Skip to content

ADP-Ribosylation Inhibitor for Treatment of Cancer

The inhibitor has confirmed engagement in cells without toxic effects and have targeted therapeutic potential

Published: 29th June 2022
ADP-Ribosylation Inhibitor for Treatment of Cancer
ibreakstock, https://stock.adobe.com/uk/348284036, stock.adobe.com
IP Status
  • Patented
  • Patent application submitted
Seeking
  • Licensing
  • Development partner
  • Commercial partner